New firms show the power of brands

New firms spun off from larger companies sometimes rise quickly, like Carrier and Otis. That’s probably because investors are familiar with their products and like their prospects. However, others such as Viatris and Kyndryl, are more obscure and need a few years to build a.. Read More

Haleon sale funds new acquisition

PFIZER INC. $49 is a buy. The prescription drugmaker (New York symbol PFE; Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $274.4 billion; Dividend yield: 3.3%; Takeover Target Rating: Medium; www.pfizer.com) merged its consumer drug business with GlaxoSmithKline (New York symbol GSK) in 2019.
Glaxo now plans to… Read More

Drugmaker opts for spinoff over sale

Pharmaceutical giant GlaxoSmithKline recently rejected a takeover offer from Unilever for its consumer drug business and will continue with its original plan to spin it off as a separate company.
The spinoff will let Glaxo better focus on its main prescription drug and vaccine operations. We… Read More